Ascenda claims fired COO tried to swap IP for $39m

Molecular testing company Ascenda BioSciences is suing a former chief operations officer, claiming he attempted to “extort” the return of sensitive company information before taking up employment with a direct competitor.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

22 October 2026 Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.

Pharma

Amarin and Hikma call time on six-year skinny label fight

22 October 2026 Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.

Pharma

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

20 October 2026 In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.

More features

UK unveils £1bn sector investment push after recent setbacks

Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos

Oura targets Ultrahuman’s redesigned smart ring following import ban

Weil collapse leaves IP talent facing uncertain future after major expansion

Meril turns the tables on Edwards with European patent revocation

Latham lands pharma and tech expert in London

Regeneron and Amgen call a truce on two Eylea biosimilar patents

HeartFlow targets AI cardiac imaging rival over patents and trade secrets

Ascenda claims fired COO tried to swap IP for $39m

More on this story

Editor's picks

Editor's picks

More features